Loader

Pathways

PathWhiz ID Pathway Meta Data

PW144869

Pw144869 View Pathway
drug action

Clopidogrel Drug Metabolism Action Pathway

Homo sapiens

PW124569

Pw124569 View Pathway
metabolic

Clopidogrel Metabolic Pathway

Homo sapiens
85-90% of an oral dose undergoes first pass metabolism by carboxylesterase 1 in the liver to an inactive carboxylic acid metabolite. About 2% of clopidogrel is oxidized to 2-oxoclopidogrel. This conversion is 35.8% by CYP1A2, 19.4% by CYP2B6, and 44.9% by CYP2C194 though other studies suggest CYP3A4, CYP3A5, and CYP2C9 also contribute. 2-oxoclopidogrel is further metabolized to the active metabolite. This conversion is 32.9% by CYP2B6, 6.79% by CYP2C9, 20.6% by CYP2C19, and 39.8% by CYP3A4.

PW000586

Pw000586 View Pathway
drug metabolism

Clopidogrel Metabolism Pathway

Homo sapiens
Clopidogrel, marketed as Plavix, is an antiplatelet drug that targets the P2Y12 receptor of platelets. Clopidogrel is taken orally as a prodrug, and must be metabolically activated before it can be effective. It first enters the liver and enters the endoplasmic reticulum where it is metabolized to form the active metabolite. First, it is catalyzed by cytochromes P450 2C19, 2B6 and 1A2 into 2-oxoclopidogrel. Secondly, it is processed by cytochromes P450 2B6, 2C9, 2C19, 3A4, 3A5, and serum paraoxonase/arylesterase 1 into the active metabolite of clopidogrel. The active metabolite of clopidogrel then enters the blood stream, where it binds irreversibly to the P2Y purinoreceptor 12 on the surface of platelet cells, preventing ADP from binding to and activating it. Clopidogrel prevents the activation of the Gi protein associated with the P2Y12 receptor from inactivating adenylate cyclase in the platelet, leading to a buildup of cAMP. This cAMP then activates calcium efflux pumps, preventing calcium buildup in the platelet, which would cause activation, and later, aggregation.

PW146999

Pw146999 View Pathway
metabolic

Clorazepate Drug Metabolism Pathway

Homo sapiens

PW127704

Pw127704 View Pathway
drug action

Clorazepic Acid Action Pathway

Homo sapiens
Clorazepic acid or clorazepate is a benzodiazepine used to treat anxiety, partial seizures, and alcohol withdrawal. Clorazepate is indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. It is also used as adjunctive therapy in the management of partial seizures and for the symptomatic relief of acute alcohol withdrawal. Clorazepate is a benzodiazepine with depressant effects on the central nervous system.8 Benzodiazepines are able to enhance the binding of gamma-aminobutyric acid (GABA) to the GABA type A (GABA-A) receptor by binding to a region in the extracellular domain found at the interface between the alpha (α) and gamma (γ) subunits of the GABA-A receptor. The interaction of GABA and the GABA-A receptor promotes channel opening, leading to an increased chloride influx. Consequently, the use of benzodiazepines, such as clorazepate, leads to neuronal hyperpolarization. Clorazepate is a prodrug for nordiazepam which is converted in the liver. Some side effects of using clorazepic acid may include dizziness, nervousness, blurred vision, and headache.

PW176011

Pw176011 View Pathway
metabolic

Clorazepic acid Predicted Metabolism Pathway new

Homo sapiens
Metabolites of Clorazepic acid are predicted with biotransformer.

PW132553

Pw132553 View Pathway
metabolic

Clothiapine Drug Metabolism

Homo sapiens
Clothiapine is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Clothiapine passes through the liver and is then excreted from the body mainly through the kidney.

PW146623

Pw146623 View Pathway
drug action

Clothiapine Drug Metabolism Action Pathway

Homo sapiens

PW127706

Pw127706 View Pathway
drug action

Clotiazepam Action Pathway

Homo sapiens
Clotiazepam is a thienodiazepine used to manage anxiety disorders and insomnia. Clotiazepam (marketed under brand name Clozan, Distensan, Trecalmo, Rize, Rizen and Veratran) is a thienodiazepine drug which is a benzodiazepine analog. Clotiazepam binds to the benzodiazepine site of the GABAA receptor where it acts as a full agonist; this action results in an enhanced GABA inhibitory effect at the GABAA receptor which results in the pharmacological effects of clotiazepam. Clotiazepam acts at the benzodiazepine receptors (BZD). This agonizes the action of GABA, increasing the frequency of opening of the channel chlorinates and penetration of the ions chlorinates through the ionophore. Increase in membrane polarization decreases the probability of discharge of neurons. Some side effects of using Clotiazepam may include drowsiness, lightheadedness, and vertigo.

PW145444

Pw145444 View Pathway
drug action

Clotiazepam Drug Metabolism Action Pathway

Homo sapiens